Table 2 Patient characteristics: PET positive vs. PET negative
Characteristic | PET positive | PET negative |
|---|---|---|
Number | 92 | 37 |
Age (years) at PSMA PET (median, range) | 72 (49–86) | 72 (47–80) |
Gleason Score [pts] | ||
 6 | 8 (8.7%) | 3 (8.1%) |
 7a | 19 (20.7%) | 8 (21.6%) |
 7b | 23 (25.0%) | 14 (37.8%) |
 8 | 13 (14.1%) | 5 (13.5%) |
 9 | 27 (29.3%) | 7 (18.9%) |
 10 | 2 (2.2%) | – |
Risk group (D’Amico) [pts] | ||
 low | 3 (3.3%) | 2 (5.4%) |
 intermediate | 14 (15.2%) | 7 (18.9%) |
 high | 75 (81.5%) | 28 (75.7%) |
PSA PRE-PSMA PET [ng/ml] (median/mean, range) | 1.90/8.27 (0.14–150.0) | 0.30/0.50 (0.13–3.24) |
PSA doubling time | ||
  ≤ 10 months | 56 (77.8%) | 25 (67.6%) |
  > 10 months | 16 (22.2%) | 12 (32.4%) |
ADT at time of PET [pts] | 12 (13.0%) | 2 (5.4%) |
Activity of 68Ga-PSMA-HBED-CC [MBq] (mean, range) | 191.96 (87–293) | 186.78 (94–293) |